Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Financing Activities (2021 - 2025)

Krystal Biotech's Cash from Financing Activities history spans 5 years, with the latest figure at $15.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 545.22% year-over-year to $15.7 million; the TTM value through Dec 2025 reached $8.7 million, down 67.78%, while the annual FY2025 figure was $8.7 million, 67.78% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $15.7 million at Krystal Biotech, up from $3.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $202.1 million in Q4 2021 and bottomed at -$12.5 million in Q1 2025.
  • The 5-year median for Cash from Financing Activities is $3.2 million (2022), against an average of $31.1 million.
  • The largest annual shift saw Cash from Financing Activities surged 15527.14% in 2022 before it plummeted 217.79% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $202.1 million in 2021, then crashed by 98.48% to $3.1 million in 2022, then decreased by 14.66% to $2.6 million in 2023, then decreased by 7.29% to $2.4 million in 2024, then soared by 545.22% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Cash from Financing Activities are $15.7 million (Q4 2025), $3.7 million (Q3 2025), and $1.8 million (Q2 2025).